Our invention of a new class of antimicrobial drug with novel mode of action means our drugs are promising, not only in terms of its antimicrobial activities, but also in helping patients suffering from current drug-resistant bacterial infections as we could provide new and effective medication options, especially against the multidrug-resistant bacteria. The provision of alternative antimicrobial therapeutics could also alleviate the financial burden incurred in drug resistant infections arose from the higher medical costs, longer hospital stays, and the loss of productivity (estimated to cost around £66 trillion globally by 2050) of the patients.